EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 3 trial

Yuzhuo Yang, Xiansheng Zhang, Tao Jiang, Lianming Zhao, Fubiao Li, Wenliang Yao, Junhong Deng, Xiangsheng Zhang, Jin Yang, Zhigang Ji, Zhigang Tong, Yun Chen und 4 weitere

The Journal of Sexual Medicine · 2025

DOI: 10.1093/jsxmed/qdaf109 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Yuzhuo Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Peking University First Hospital, Beijing, 100034, China. Hauptthemen laut MEDLINE: Erectile Dysfunction, Phosphodiesterase 5 Inhibitors, Sulfonamides, Pyrimidines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Vigonvita Life Sciences Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Simenafil, a potent and highly selective oral phosphodiesterase type 5 (PDE5) inhibitor, is currently under investigation for erectile dysfunction (ED) treatment.

Aims

To evaluate the efficacy and safety of simenafil for ED treatment.

Methods

This was a multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 3 study in men aged 18-75 years with a history of ED of 6 months or more. The subjects were randomized in a ratio of 1:1:1:1 to on-demand receive fixed-dose either placebo or simenafil (2.5 mg, 5 mg or 10 mg) for 12 weeks. Outcomes Primary efficacy endpoints were the least square mean (LSM) changes from baseline to week 12 in the erectile function (EF) domain of the International Index of Erectile Function (IIEF), percentages of “yes” responses to sexual encounter profile (SEP) diary question 2 (SEP Q2: Were you able to insert your penis into your partner’s vagina?) and question 3 (SEP Q3: Did your erection last long enough for you to have successful intercourse?)

Results

A total of 765 patients were randomized and 92.3% completed the study. The mean age of subjects was 41.3 years and 81.6% had moderate to severe ED (mean overall International Index of Erectile Function–Erectile Function (IIEF-EF) domain score 13.4). After 12 weeks of treatment, doses of 2.5, 5, and 10 mg of simenafil exhibited substantial increases than placebo in IIEF-EF score (12.3, 12.3, 12.7 vs. 9.6), the percentages of “yes” responses to SEP Q2 (40.58%, 42.43%, 43.98% vs. 32.05%), and SEP Q3 (61.91%, 63.70%, 65.19% vs. 46.70%) (all P < .001). Adverse drug reactions (ADRs) occurred in 36.2% of patients who received simenafil (32.6% in simenafil 5 mg group, the clinically recommended dose) and in 30.9% of those who received placebo. The most common (≥2%) ADRs were dizziness, headache, flushing, nasal congestion, and dry mouth, and most were mild or moderate. Furthermore, abnormal vision (PDE6 related) and myalgia (PDE11 related) did not occur in patients who received simenafil. Clinical Implications Simenafil is highly effective in all 3 dose groups and has a low effective dose and good safety profile, providing a novel, favorable treatment option for patients with ED. Strengths and Limitations The efficacy and safety evaluation of simenafil in difficult-to-treat patients with ED, ED patients with other concomitant diseases, and other ethnic populations was not performed.

Conclusion

Simenafil is an effective and well-tolerated therapy for patients with ED.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erectile DysfunctionPhosphodiesterase 5 InhibitorsSulfonamidesPyrimidinesHumansMaleDouble-Blind MethodMiddle AgedAdultAgedTreatment OutcomeYoung AdultAdolescentDose-Response Relationship, DrugPenile Erection

Stichwörter der Autor:innen

clinical trialefficacyerectile dysfunctionphosphodiesterase type 5 inhibitorssafetysimenafil

Substanzen

Phosphodiesterase 5 InhibitorsSulfonamidesPyrimidines

Autor:innen und Institutionen

  • Department of Urology, Peking University First Hospital, Beijing, 100034, China.
  • Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
  • Department of Andrology and Sexual Medicine, Institute of Sexual Medicine, the Second Hospital of Dalian Medical University, Dalian, 116023, China.
  • Department of Urology, Peking University Third Hospital, Haidian District, Beijing, 100191, China.
  • Department of Andrology, the First Bethune Hospital of Jilin University, Changchun, 130021, China.
  • Department of Andrology, Nanchang Reproductive Hospital, Nanchang, 330004, China.

Förderung

  • Vigonvita Life Sciences Co., Ltd

Zitieren

APA

Yang, Y., Zhang, X., Jiang, T., Zhao, L., Li, F., Yao, W., Deng, J., Zhang, X., Yang, J., Ji, Z., Tong, Z., Chen, Y., Wang, Z., Juan, J., Duan, H., & Jiang, H. (2025). Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 3 trial. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf109

Vancouver

Yang Y, Zhang X, Jiang T, Zhao L, Li F, Yao W, et al. Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 3 trial. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdaf109

BibTeX
@article{Yang2025,
  author = {Yang, Yuzhuo and Zhang, Xiansheng and Jiang, Tao and Zhao, Lianming and Li, Fubiao and Yao, Wenliang and Deng, Junhong and Zhang, Xiangsheng and Yang, Jin and Ji, Zhigang and Tong, Zhigang and Chen, Yun and Wang, Zhen and Juan, Jiaxiang and Duan, Huaqing and Jiang, Hui},
  title = {Efficacy and safety of simenafil in men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group, phase 3 trial},
  journal = {The Journal of Sexual Medicine},
  year = {2025},
  doi = {10.1093/jsxmed/qdaf109}
}
Kostenlos starten →